Jenscare's 2025H1 Results: Achievements and Financial Overview
Jenscare’s Interim Results for 2025H1
Jenscare Scientific Co., Ltd. (HKEX: 9877), a leader in innovative medical devices, has recently unveiled its interim results for the first half of 2025. The company is committed to enhancing interventional treatments specifically targeting structural heart diseases. This article will delve into key achievements in product development, commercialization strides, and the financial performance that reflects Jenscare’s growth trajectory.
Commercialization and Clinical Progress
The journey of Jenscare through the first half of 2025 has been marked by significant advancements across its product line.
LuX-Valve Series and TTVR System
In China, the multicenter clinical trial for NMPA approval has progressed to the long-term follow-up phase. This essential trial is yielding promising results. Additionally, the randomized controlled trial (RCT) focused on optimized medical therapy (OMT) has successfully completed subject enrollment, with the registration application now accepted by NMPA, marking an exciting phase in the registration process.
In Europe, the LuX-Valve Plus has reached a critical milestone, completing the 6-month follow-up of the TRINITY study, its clinical trial for CE Marking, and is currently under registration review.
Across the ocean, in the United States, the IDE Early Feasibility Study (EFS) for LuX-Valve Plus has also completed its enrollment phase. The company is pleased to announce that it has received reimbursement for device-related expenses from CMS, indicating a solid step toward securing approval for the Pivotal Study.
Ken-Valve and TAVR (AR) System
Following its approval from NMPA, the Ken-Valve has made a swift entry into the market. Jenscare has been proactive in its commercialization efforts, facilitating smooth progress in its adoption by hospitals. This valve is specifically designed for aortic regurgitation, providing solutions for patients with large annuli, a noted clinical need in interventional cardiology.
JensClip and TMVr System
The JensClip's registration application has been submitted to NMPA, indicating a new phase in its rollout. The globalization of JensClip is also in full swing, with pre-commercialization implantations taking place internationally, showcasing effective performance metrics. Activities aimed at securing CE Marking for JensClip are presently underway, further emphasizing the company’s commitment to expanding its global footprint.
Financial Highlights: Strong Sales Performance
From a financial perspective, Jenscare’s latest results present a compelling narrative of growth.
Revenue and Profit Status
Total revenue for the first half of 2025 stood at an impressive US$ 3.6 million, underscoring the company’s robust market presence. The gross profit reached US$ 1.7 million, while the sales profit was clocked at US$ 1.1 million, highlighting a commendable gross profit margin close to 90% and a sales profit margin approaching 60%. These figures reveal that Jenscare is not only generating substantial sales but is also managing costs effectively, contributing to its profitability.
Adjusted Earnings Insights
The company reported an adjusted non-IFRS loss of US$ 12.9 million, which is a slight reduction of about 3% compared to the previous year’s corresponding period. This decrease indicates Jenscare's ongoing efforts to optimize operations and reduce losses, demonstrating resilience in a competitive market.
Cash Flow and Operating Status
Currently, Jenscare maintains a strong cash position, with cash and cash equivalents, along with term deposits and financial assets totaling US$ 84.6 million. The net cash used in operating activities has also decreased, amounting to US$ 13 million—an approximate reduction of 15% compared to 2024H1. This prudent cash management illustrates the company's strategic focus on long-term sustainability and growth.
Conclusion
In summary, Jenscare Scientific Co., Ltd. is paving the way for significant advancements in the medical device sector, particularly in the treatment of heart diseases. The achievements highlighted in its 2025H1 interim results provide a comprehensive overview of its product advancements and solid financial performance, positioning the company well for future growth.
Frequently Asked Questions
What significant milestones did Jenscare achieve in 2025H1?
Jenscare made notable advancements in product development and commercialization, particularly with the LuX-Valve Series and Ken-Valve.
What is the total revenue reported by Jenscare for 2025H1?
The total revenue for Jenscare was US$ 3.6 million for the first half of 2025, showcasing strong performance.
How has Jenscare's adjusted loss changed compared to previous periods?
The adjusted non-IFRS loss was US$ 12.9 million, indicating a slight decrease of about 3% from 2024H1.
What does Jenscare’s cash position indicate?
The company holds US$ 84.6 million in cash and equivalents, reflecting strong financial health and operational stability.
What are the next steps for Jenscare regarding its products?
Jenscare plans to advance registration processes and enhance commercialization efforts, with a keen focus on global market expansion.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
